Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Neonatology ; 104(3): 184-7, 2013.
Article in English | MEDLINE | ID: mdl-23970042

ABSTRACT

Extremely low birth weight (ELBW; <1,000 g) infants have poor outcomes, often compromised by bilirubin neurotoxicity. We measured unbound bilirubin (Bf) and unbound free fatty acid (FFAu) levels in 5 ELBW infants in a trial examining the effects of pharmacologic ductal closure on infants treated with Intralipid infusion (3 g/kg/day). The levels for all infants (mean ± SD) were: total serum bilirubin (TSB) 4.6 ± 1.7 mg/dl, FFAu 376 ± 496 nM, and Bf 42 ± 30 nM. Of the 3 infants who died, 2 had TSB <5.9 mg/dl but FFAu >580 nM and Bf >75 nM. Multiple regression revealed a major effect on Bf levels due to FFAu, indicating that Intralipid elevated levels of FFAu and Bf. Indomethacin or ibuprofen reduced Bf levels, most likely by reducing FFAu levels through lipase inhibition. Because displacement of Bf by FFAu decouples Bf from TSB, phototherapy may not reduce the risk of bilirubin or FFAu toxicity in Intralipid-treated ELBW infants.


Subject(s)
Bilirubin/blood , Fatty Acids, Nonesterified/blood , Infant, Extremely Low Birth Weight/blood , Phospholipids/administration & dosage , Phototherapy , Soybean Oil/administration & dosage , Emulsions/administration & dosage , Humans , Infant, Newborn , Male , Pilot Projects , Regression Analysis
2.
J Matern Fetal Neonatal Med ; 25(8): 1483-7, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22272724

ABSTRACT

OBJECTIVE: To study the association between Sirtuin1 (Sirt1), a class III histone deacetylator, in tracheal aspirate (TA) leukocytes and the development of bronchopulmonary dysplasia (BPD) in premature infants and modulation of Sirt1 with dexamethasone (Dex) use. DESIGN/METHODS: Serial TA samples were collected on days 1, 3, 5 and 7 from ventilated premature neonates. Sirt1 was localized by immunocytochemistry and quantified on a scale of 0-4 by blinded observers. BPD was defined as the need of supplemental oxygen at 36 weeks postmenstrual age (PMA). RESULTS: A total of 130 TA samples were collected from 51 infants (mean ± SD: GA 25.5 ± 1.4 w, BW 762 ± 174 g). Eleven infants survived without BPD and 40 infants died before 36 weeks PMA or developed BPD. Sirt1 was localized in the cytoplasm and nuclei of mononuclear (MONO) as well as polymorphonuclear cells. Sirt1 was significantly more localized in the nuclei of MONO cells in infants without BPD compared to infants who developed BPD or died before 36 weeks PMA. Twenty six infants received Dex. There was no significant change in Sirt1 localization with steroid therapy. CONCLUSIONS: Lower Sirt1 in TA leukocytes is associated with the development of BPD or death in premature infants. Dex use had no effect on Sirt1.


Subject(s)
Bronchopulmonary Dysplasia/etiology , Infant, Premature , Leukocytes/chemistry , Sirtuin 1/analysis , Trachea/chemistry , Biopsy, Needle , Bronchopulmonary Dysplasia/drug therapy , Bronchopulmonary Dysplasia/mortality , Bronchopulmonary Dysplasia/pathology , Cohort Studies , Dexamethasone/therapeutic use , Female , Gestational Age , Humans , Infant Mortality , Infant, Newborn , Infant, Premature/metabolism , Leukocytes/metabolism , Leukocytes/pathology , Male , Sirtuin 1/metabolism , Sirtuin 1/physiology , Trachea/metabolism , Trachea/pathology
3.
Obstet Gynecol ; 111(4): 921-6, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18378752

ABSTRACT

OBJECTIVE: To estimate if exposure to antenatal corticosteroids was associated with decreased rate of death in neonates born at 23 weeks of gestation. METHODS: This is a retrospective cohort study performed at three tertiary centers of neonates born at 23 weeks of gestation between 1998 and 2007. Stillbirths, voluntary terminations, or parental elected nonresuscitations were excluded. Clinical and demographic variables were examined to determine possible confounding variables. A multivariable logistic regression model was used to assess the effect of steroids on the odds of death after adjustment for these confounders. RESULTS: The sample included 181 neonates. Of the multiple variables examined (institution, race, diagnosis, illicit drug use, antibiotics, assisted reproduction, birth weight, gender, and route of delivery), only multiple gestations were significantly associated (P

Subject(s)
Betamethasone/therapeutic use , Dexamethasone/therapeutic use , Glucocorticoids/therapeutic use , Infant Mortality , Infant, Premature , Betamethasone/administration & dosage , Dexamethasone/administration & dosage , Female , Glucocorticoids/administration & dosage , Humans , Infant, Newborn , Logistic Models , Male , Obstetric Labor, Premature/mortality , Odds Ratio , Pregnancy , Retrospective Studies , Survival Analysis
4.
Pediatr Res ; 62(4): 483-8, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17667842

ABSTRACT

Nuclear factor-kappaB (NF-kappaB) plays a central role in regulating key proinflammatory mediators. The activation of NF-kappaB is increased in tracheal aspirate (TA) cells from premature infants developing bronchopulmonary dysplasia (BPD). We studied the effect of azithromycin (AZM) on the suppression of NF-kappaB activation and the synthesis of pro-inflammatory cytokines IL-6 and IL-8 by TA cells obtained from premature infants. Tracheal aspirate cells were stimulated with tumor necrosis factor-alpha (TNF-alpha) and incubated with AZM. The nuclear NF-kappaB-DNA binding activity, the levels of inhibitory kappaB-alpha (IkappaB-alpha) in the cytoplasmic fraction and IL-6 and IL-8 release in the cell culture media were measured. Stimulation of TA cells by TNF-alpha increased the activation of NF-kappaB, which was suppressed by the addition of AZM. Increased activation of NF-kappaB was also associated with increased levels of pro-inflammatory cytokines (IL-6 and IL-8). AZM significantly reduced the IL-6 and IL-8 production to the levels similar to control. TNF-alpha stimulation also increased the degradation of IkappaB-alpha, which was restored with the addition of AZM. Our data suggest that AZM therapy may be an effective alternative to steroids in reducing lung inflammation and prevention of BPD in ventilated premature infants.


Subject(s)
Anti-Bacterial Agents/pharmacology , Azithromycin/pharmacology , Infant, Premature/metabolism , Interleukin-6/biosynthesis , Interleukin-8/biosynthesis , NF-kappa B/metabolism , Respiration, Artificial , Trachea/metabolism , Anti-Bacterial Agents/therapeutic use , Azithromycin/therapeutic use , Bronchopulmonary Dysplasia/etiology , Bronchopulmonary Dysplasia/metabolism , Bronchopulmonary Dysplasia/prevention & control , Cell Count , Cells, Cultured , Dose-Response Relationship, Drug , Female , Gestational Age , Humans , I-kappa B Proteins/metabolism , Infant, Newborn , Male , NF-KappaB Inhibitor alpha , Respiration, Artificial/adverse effects , Suction , Trachea/pathology , Tumor Necrosis Factor-alpha/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...